This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: reduced ejection fraction

Introduction

July 2019 Br J Cardiol 2019;26(suppl1):S3 doi:10.5837/bjc.2019.s01

Introduction

Pardeep S Jhund, John J V McMurray

Abstract

The PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) study is the key randomised-controlled trial that underpins the clinical use of sacubitril/valsartan, which demonstrated significantly improved clinical outcomes in patients with HFrEF, in comparison with angiotensin-converting enzyme (ACE) inhibition.1 Patients with HFrEF in the routine-care setting represent a clinically heterogeneous population, with a high incidence of comorbidities. Our first article dives deep into the PARADIGM-HF data, and presents the results of key subgroup analyses that support the use o

| Full text
Applying PARADIGM-HF to the use of sacubitril/valsartan in clinical practice

July 2019 Br J Cardiol 2019;26(suppl 1):S4-S8 doi:10.5837/bjc.2019.s02

Applying PARADIGM-HF to the use of sacubitril/valsartan in clinical practice

Pardeep S Jhund, John J V McMurray

Abstract

Introduction The PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial demonstrated that the angiotensin receptor/neprilysin inhibitor (ARNI), sacubitril/valsartan (formerly known as LCZ696), was superior to enalapril in reducing the occurrence of adverse cardiovascular (CV) outcomes in patients with heart failure with reduced ejection fraction (≤40%; HFrEF).1,2 The trial was terminated early, on the advice of the independent safety monitoring board, on the basis of clear benefits. These included:1 a 20% relative risk reduction (4.7% absolute risk reduction [ARR

| Full text
Prevalence, clinical characteristics and outcomes of HF with preserved versus reduced ejection fraction

February 2016 Br J Cardiol 2016;23:(1) doi:10.5837/bjc.2016.005 Online First

Prevalence, clinical characteristics and outcomes of HF with preserved versus reduced ejection fraction

Rajdip Dulai, Azeem S Sheikh, Amer Qureshi, Shanit Katechia, Yulia Peysakhova, Moira Johns, Sajjad Mazhar

Abstract

Introduction Heart failure is a significant and rising public health problem affecting 900,000 people in the UK, and accounts for 5% of all emergency admissions.1 This rising trend is set to continue as the average age of the population increases.1-3 It is estimated that the proportion of patients with heart failure with preserved ejection fraction (HFPEF) is between 30% and 50%.4-9 As a result, in recent years, more attention has been paid to this cohort of patients. However, there is still limited information regarding outcomes and treatment for these patients. Previous reports have shown that patients that have HFPEF are more likely to be

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now